Recommencement of atezolizumab with associated pulmonary sarcoid ‐like reaction
An 81 year old male with Child-Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated with 3-weekly atezolizumab and bevacizumab developed a pulmonary sarcoid-like reaction (SLR) after 5 months. Atezolizumab was identified as the likely culprit. He was treated with prednisolone, resul ting in improvement, and was successfully rechallenged with both atezolizumab and bevacizumab. AbstractAn 81 year old male with Child-Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated with 3-weekly atezolizumab and bevacizumab developed a pulmonary sarcoid-like reaction (SLR) after 5 months. Atezolizumab, an immune checkpoint inhibitor, was identified as the likely culprit. He was treated with prednisolone, resulting in improvement, and was successfully rechallenged with both atezolizumab and bevacizumab.
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Khai Tam,
Michael Wallace,
Siobhain Mulrennan Tags: CASE REPORT Source Type: research
More News: Avastin | Cancer & Oncology | Carcinoma | Children | Cirrhosis | Hepatocellular Carcinoma | Liver Cancer | Prednisolone | Respiratory Medicine | Sarcoidosis